Prescient Therapeutics announces share purchase plan to raise $8 million

Prescient Therapeutics managing director and CEO Steven Yatomi-Clarke speaks with Proactive’s Elisha Newell about the company’s announcement of a share purchase plan (SPP), looking to raise $8 million. Yatomi-Clarke discusses using the raised funds to progress PTX’s cancer therapies as well as putting some towards general working capital and costs of the offer. He also shares the company’s plan for the remainder of this year. #PrescientTherapeutics #asx # proactiveaustralia
#cancertherapy

You might like

© 2022 Stockmark.it The Latest StockMarket News and Interviews